The FDA Is Watching These 14 Drugs for Serious Side Effects

The FDA is watching these 14 drugs for serious side effects.

Every 3 months, the FDA reviews and publishes reports of adverse reactions from medications they have received through the FDA Adverse Event Reporting System (FAERS) .The FDA has been posting these quarterly updates since 2007, due to an update to the U.S Food and Drug Administration. Amendments Act that requires the FDA to publish a new list of potential signals of serious risks/new safety information identified every 3 months.

Should I be worried if any prescription is on the list??

The FDA does emphasize that just because a medication appears this list, it doesn’t mean that they have determined that the drug actually carries a risk. Following the quarterly update, the FDA will complete an evaluation of each potential safety issue and make additional announcements if they find anything further. At the end of the June 2017, the FDA released the list of medications for the first quarter (January-March) that potentially carries serious risks. So which prescription is the FDA monitoring this quarter???

1. Product Name: ALLI (OSLISTAT) capsules,

2. XENICAL (ORLISTAT) capsules for oral use

Potential Risk : Orlistat and neuropsychiatric adverse events

Additional Information: FDA is evaluating the need for regulatory action

3. PRODUCT NAME: CUBICIN (DAPTOMYCIN FOR INJECTION) FOR INTRAVENOUS USE,

4. CUBICIN RF (DAPTOMYCIN FOR INJECTION) FOR INTRAVENOUS USE

Potential Risk : Medication error

Additional Information: The container labels and carton labeling were revised. In addition the dosage and administration section of the labeling was updated to better differentiate the two formulations. Cubicin labeling, Cubicin RF labeling.

Lets put this sticker on our cars and spread awareness

You can get this sticker from here

5. EXJADE (DEFERASIROX)Tablets for oral suspension ,JADENU (DEFERASIROX) tablets for oral use

Potential Risk : Pediatric fever and dehydration

Additional Information: FDA is evaluating the need for regulatory action.

6. Gonadotropin releasing hormone (Gnrh) Agonist

>>LUPRON (LEUPROLIDE ACETATE) injection,

>> LUPRON DEPOT PED (LEUPROLIDE ACETATE for depot injection),

>> POWDER,LYOPHLIZED,for suspension,

>> SUPPRELIN LA( HISTRELIN ACETATE) Subcutaneour Implant.

>> SYNAREL(NAFARELIN ACETATE) Nasal Solution

Potential Risk : Musculoskeletal and connective tissue pain and discomfort ADDITIONAL INFORMATION: FDA is evaluating the need for regulatory action.

• >>KEPPRA (LEVETIRACETAM) Tablets for oral use
• >>KEPPRA (LEVETIRACETAM) Extended Release tablets for oral use
• >>KEPPRA (LEVETIRACETAM) Oral solution R
• >>KEPPRA (LEVETIRACETAM) Injection, For intravenous use

Potential Risk : Acute kidney injury and interstitial nephritis

Additional Information: The adverse reactions, post marketing experience section of the labeling for Keppra and keppra XR was updated to include acute kidney injury.

7. KEYTRUDA (PEMBEOLIZUMAB) for injection for intravenous use, OPDIVO (NIVOLUMAB) for injection, for intravenous use, YERVOY (IPILIMUMAB) injection, for intravenous use

Potential Risk :Ocular toxicities including vision loss and retinal detachment

Additional Information: FDA is evaluating the need for regulatory action.

8. KYBELLA (DEOXYCHOLIC ACID) injection, for subcutaneous use

Potential Risk : Injection site infection and necrosis

Additional Information: FDA is evaluating the need for regulatory action.

9. METHIMAZOLE TABLETS:

Potential Risk : Rhabdomyolysis in methimazole 

Additional Information : FDA decided that no action is necessary at this time, based on available information.

10. NEULASTA ONPRO KIT (PEGFILGRASTIM) injection, for subcutaneous use

Potential Risk : Device failure

Additional Information : FDA is evaluating the need for regulatory action.

11. OFEV (NINTEDANIB) capsules, for oral use

Potential Risk : Liver dysfunction

Additional Information: FDA is evaluating the need for regulatory action.

12. SODIUM GLUCOSE COTRANSPORTER- 2(SGLT-2) INHIBITORS

• >>>FARXIGA (DAPAGLIFLOZIN) tablets, for oral use
• >>>GLYXAMBI (EMPAGLIFLOZIN AND LINAGLIPTIN) tablets, for oral use
• >>>INVOKAMET XR (CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE) tablets, for oral use
• >>>INVOKANA (CANAGLIFLOZIN) tablets, for oral use
• >>>JARDAINCE (EMPAGLIFLOZIN) tablets, oral use
• >>>SYNJARDY (EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE) tablets, for oral use
• >>>SYNJARDY XR (EMPAGLIFLOZIN and METFORMIN HYDROCHLORIDE EXTENDED-RELEASE) tablets, for oral use
• >>>XIGDUO XR (DAOAGLIFLOZIN and METFORMIN HYDROCHLORIDE EXTENDED-RELEASE) tablets, for oral use

Potential Risk : Nephrolithiasis ADDITIONAL INFORMATION: FDA decided that no action is necessary at this time, based on available information.

13. STELARA (USTEKINUMAB) injection, for subcutaneous use

Potential Risk : Interstitial pneumonia ADDITIONAL INFORMATION: FDA is evaluating the need for regulatory action.

• >>>TANZEUM (ALBIGLUTIDE) for injection, foe subcutaneous use
• >>>TRULICITY (DULAGLUTIDE) injection, for subcutaneous use

Potential Risk : Serious hypersensitivity reactions. ADDITIONAL INFORMATION: FDA is evaluating the need for regulatory action.

14. ULORIC (FEBUXOSTAT) tablets, for oral use

Potential Risk: Drug reaction with Eosinophilia and systemic symptoms. ADDITIONAL INFORMATION: FDA is evaluating the need for regulatory actions.  

Fibromyalgia No Energy: Special Winter collection for fibro warriors. I have fibromyalgia, i don’t have the energy to pretend that i like you. Pull over Hoodie, Long sleeve Tee, Tote Bag and much more Get 1 for your friend and save on shipping. Click here to get this.

Click Here to Get this

Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS): January – March 2017

What is the FDA doing about all of these reports??

Unless otherwise noted, the FDA is currently evaluating the need for further action on all of the medications on the list. What should I do if I take one of these medications? First, I don’t stop taking your prescription without speaking to your doctor, this can cause more problems than it solves. If you have any concerns or if you think you are experiencing one of these side effects, talk to your  pharmacist.

How can we report a problem with a drug to FDA??

IF you need to report a serious problem with a medication to the FDA, you can do so through their MedWatch website. The MedWatch allows you to voluntarily report a serious adverse event, product quality problem, product use error, or therapeutic in equivalence/failure that you suspect is associated with the use of an FDA-regulated drug, biologic, medical device, dietary supplement or cosmetic. You can report suspected counterfeit medical products here as well.

by- Dr.Muneeba Rana, MD MBBS, FUMDC. SHARE WITH YOUR LOVED ONES TAKING THESE MEDICATIONS

Click Here to get this shirt

Click Here to Visit Store for More Products

For support and discussions join the group “Living with fibromyalgia and chronic illness”

Reference: The post the FDA is watching these 14 drugs for serious side effects appeared first on the GoodRx prescription saving blog, Via GoodRx.

Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS): January – March 2017 from FDA